Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Two Tamsulosin Formulations in Healthy Males
NCT02417831Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2015
- Primary completion
- May 2015
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of tamsulosin in benign prostatic hyperplasia (BPH) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Plasma Concentration at 72 hours, Area Under the Curve to Last Quantifiable Time Point at 72 hours and 1 more. Started Apr 2015; status: completed.
02
Drugs
tamsulosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT02417831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02417831.